| 柯华,刘咏梅,陈维永,周陈娇,李小波,邹雪林.贝伐珠单抗联合化疗对肺腺癌患者恶性胸腔积液的疗效及安全性研究[J].中国临床保健杂志,2019,22(4):484-487. |
| 贝伐珠单抗联合化疗对肺腺癌患者恶性胸腔积液的疗效及安全性研究 |
| Efficacy and safety of bevacizumab combined with chemotherapy for malignant pleural effusion in patients with lung adenocarcinoma |
| 投稿时间：2018-12-03 |
| DOI：10.3969/J.issn.1672-6790.2019.04.014 |
| 中文关键词: 癌,非小细胞肺 胸腔积液,恶性 药物疗法,联合 抗体,单克隆 治疗结果 |
| 英文关键词: Carcinoma,non-small-cell lung Pleural effusion,malignant Drug therapy,combination Antibodies,monoclonal Treatment outcome 〖FL |
| 基金项目:四川省卫生和计划生育委员会科研课题(16ZD005) |
|
| 摘要点击次数: 5718 |
| 全文下载次数: 4616 |
| 中文摘要: |
| 目的 探讨贝伐珠单抗联合化疗对肺腺癌患者恶性胸腔积液的疗效及安全性研究。 方法 选取住院治疗的92例肺腺癌患者为研究对象,并依据随机数字表法分为治疗组(n=46)和对照组(n=46)。对照组患者仅给予常规化疗,治疗组患者在对照组患者治疗的基础上加用贝伐珠单抗。比较两组患者恶性胸腔积液治疗效果；检测并比较两组患者血清肿瘤标志物水平变化；比较两组患者胸腔积液中血管内皮生长因子(VEGF)水平和卡氏功能评分(KPS)变化；统计两组患者不良反应发生情况。 结果 治疗组的恶性胸腔积液治疗效果较对照组显著升高,且两组间差异有统计学意义(P<0.05)。与治疗前相比,治疗后两组患者细胞角蛋白19片段(CK-19)、肿瘤特异性生长因子(TSGF)以及癌胚抗原(CEA)均明显降低,且治疗组显著低于对照组(P<0.05)。与治疗前相比,治疗后两组患者KPS评分明显升高,且治疗组显著高于对照组(P<0.05),胸水VEGF水平明显降低,且治疗组显著低于对照组(P<0.05)。治疗期间两组不良反应发生率经统计学比较,差异均无统计学意义(P均>0.05)。 结论 贝伐珠单抗联合化疗治疗肺腺癌患者可明显改善其临床症状,疗效佳,且安全可靠。 |
| 英文摘要: |
| Objective To investigate the efficacy and safety of bevacizumab combined with chemotherapy for malignant pleural effusion in patients with lung adenocarcinoma. Methods 92 cases of lung adenocarcinoma patients hospitalized were selected as the study subjects,and were divided into treatment group (n=46) and control group (n=46) according to the random number table method.Patients in the control group were only given chemotherapy,and patients in the treatment group were treated with bevacizumab based on the treatment of patients in the control group.Between two groups,the therapeutic effects of malignant pleural effusion were compared,the levels of serum tumor markers in the two groups were detected and compared,and VEGF levels and KPS scores in pleural effusion were compared.Adverse reactions of the two groups were statistically analyzed. Results The treatment effect of malignant pleural effusion in the treatment group was significantly higher than that in the control group,and the difference between the two groups was significant (P<0.05).Compared with that before treatment,serum CK-19,TSGF and CEA levels of the two groups were significantly decreased after treatment,with the treatment group significantly lower than those of the control group (P<0.05),the KPS score of the two groups was significantly increased after treatment,with the treatment group significantly higher than the control group (P<0.05),and the level of VEGF in pleural effusion was significantly lower,with the treatment group significantly lower than the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups during the treatment period (P>0.05). Conclusion Bevacizumab combined with chemotherapy can significantly improve their clinical symptoms in the treatment of lung adenocarcinoma patients with good efficacy and safety. |
|
查看全文
|
| 关闭 |
|
|
|